Severe Psoriasis Linked to Higher Risk of Earlier Death
But experts say there may be ways to reduce those odds Source: HealthDay Related MedlinePlus Pages: Health Statistics, Psoriasis
A biologic under investigation for severe psoriasis has topped one of the most effective therapies on the market in head-to-head phase 3 trials.Medscape Medical News
(MedPage Today) -- Outcomes didn't differ in randomized trial
A new study finds that a psoriasis drug might help to reduce heart disease risk. Overall, it reduced a particular risk marker by 19 percent.
Interleukin-17C (IL-17C) is a functionally distinct member of the IL-17 family that was implicated to play a role in the pathogenesis of psoriasis. Here we confirmed that IL-17C is involved in psoriasis and explored potential roles for IL-17C in atopic dermatitis (AD). An anti-IL-17C antibody, MOR106, was generated that potently and selectively binds to human and mouse IL-17C, thereby inhibiting the binding of IL-17C to its IL-17RE receptor. The antibody inhibited cutaneous inflammation in an IL-23-induced psoriatic-like skin inflammation model.
(MedPage Today) -- Bimekizumab brings clear or almost clear skin to vast majority of patients in phase II trial
(MedPage Today) -- Superior to ustekinumab for many endpoints in two RCTs
If you’ve been following the Wheat Belly discussions, you already know that efforts to cultivate healthy bowel flora in the wake of wheat/grain elimination is a key factor in regaining health. While I’ve emphasized the importance of a high-potency (e.g., 50 billion or more CFUs per day), multi-species probiotic supplement and prebiotic fibers, I’ve not focused on the importance of fermented foods. This issue comes to light in particular with our experience in battling small intestinal bacterial overgrowth, or SIBO. Dysbiosis, or disrupted composition of bowel flora in the colon, is exceptionally common, e...
Reductions in the impact of genital psoriasis on sexual activity seen as early as one week INDIANAPOLIS, Feb. 19, 2018 -- (Healthcare Sales &Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe ... Biopharmaceuticals, Dermatology Eli Lilly, Taltz, ixekizumab, genital psoriasis
(MedPage Today) -- Agent may also option in patients who withdrew from therapy and were re-treated